GlassScriptPhysician profile
Susan Obrien
NPI 1003290966
$7,188.64
in general payments reported to CMS, 2019-2025
31 companies · $2,426 in 2025
The $2,426 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $770 · 2023: $1,704 · 2024: $1,899 · 2025: $2,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,833 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,832.80 |
| Education | $196.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,622.55 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $714.66 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $677.06 | 2022-2025 | Dupixent |
| Harmony Biosciences LLC | $509.39 | 2023-2025 | Wakix |
| Insmed, INC. | $492.55 | 2022-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $477.88 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Mylan Specialty L.P. | $358.23 | 2021-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $346.69 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $237.72 | 2021-2025 | Glassia |
| Merck Sharp & Dohme LLC | $217.89 | 2023-2025 | Zerbaxa, Recarbrio |
| Avadel Cns Pharmaceuticals, LLC | $194.17 | 2023-2025 | Lumryz |
| Axsome Therapeutics, INC. | $188.39 | 2023-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $149.22 | 2022-2025 | Opsumit, Uptravi |
| Verona Pharma, INC. | $120.07 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $97.99 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.66 | 2022-2023 | Stiolto Respimat |
| Philips North America LLC | $88.43 | 2021-2025 | Vest Therapy Und |
| Vifor Pharma, INC. | $81.31 | 2024-2025 | Zemaira, Veltassa |
| Genentech USA, INC. | $70.43 | 2024-2025 | Xolair |
| Viatris Specialty LLC | $56.31 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $54.47 | 2023-2025 | Acthar |
| Amgen INC. | $50.28 | 2022-2023 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $48.33 | 2021-2022 | |
| Lilly USA, LLC | $45.45 | 2025 | Zepbound |
| United Therapeutics Corporation | $43.62 | 2023-2025 | Tyvaso, Tyvaso |
| Ani Pharmaceuticals, INC. | $39.52 | 2022-2024 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $28.58 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $24.31 | 2024 | Ultomiris |
| Ambu INC. | $19.17 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $18.21 | 2025 | Neffy |
| Inspire Medical Systems, INC. | $18.10 | 2023 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.